
NTHI Stock Forecast & Price Target
NTHI Analyst Ratings
Bulls say
NeOnc Technologies Hldgs is a clinical-stage biotech company with a strong focus on effective CNS drug delivery. Their lead products, NEO100 and NEO212, have shown promising results and have the potential for accelerated approval, with further research ongoing for hard-to-treat brain tumors. The company has secured funding for continued operations and management has a positive outlook on the success of these drugs.
Bears say
NeOnc Technologies Hldgs is facing several fundamental challenges that negatively impact the outlook for its stock. Firstly, the company's drug delivery method and lead product candidates, while promising, have significant technical and safety risks that may limit their effectiveness and potential application to certain types of brain tumors. Secondly, the company's financials and patent portfolio are not strong enough to overcome these challenges and successfully bring its products to market. Finally, the company's leadership team lacks the necessary experience in the biopharmaceutical industry, and their past successes may not translate to the complex and competitive field of CNS diseases.
This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
NTHI Analyst Forecast & Price Prediction
Start investing in NTHI
Order type
Buy in
Order amount
Est. shares
0 shares